EATG » R&D

R&D

Effective TB, HIV and malaria vaccines missing from drug development pipeline

Financial modeling tool reveals where global health investment falls short Many of the vaccines critically needed to fight some of the world’s most prevalent infectious diseases are not likely to…

Webinar: Patient Engagement on Medicines Research & Development

Join us for a webinar about patient engagement in the process of research and development of medicines on Thursday, September 6 from 18:00 to 19:15 CET.   Four European patient…

AIDS 2018: Addressing research gaps identified by women living with HIV in Europe and Central Asia

We are pleased to invite you to join a side-meeting at the AIDS 2018 conference that will bring together community, clinicians and researchers to discuss research gaps related to women…

Novartis drops antibiotics research program

Ceasing work on several experimental antimicrobial projects   CIDRAP News: Novartis drops antibiotic development program “Antibiotic development efforts were dealt a blow when drug maker Novartis AG announced its…

Hookipa and Gilead enter into a collaboration and license agreement to develop immunotherapies against HIV and hepatitis B

-- Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis B infections -- Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development…

Analysis links US government global health R&D funding to jobs, economic benefits across states

As White House seeks big cuts in global health research, new state-by-state analysis shows US government investment brings jobs, health security to states while saving millions of lives worldwide The…

HIVACAR: EATG reports from the second general assembly of the consortium

On March 15-16 the European AIDS Treatment Group participated in the second general assembly meeting of the HIVACAR consortium in Digem (Belgium). The EATG in collaboration with the Complutense University…

Metrodora: Call for applications in the Multi-Stakeholders’ Meeting

Call for applications: Multi-Stakeholders’ Meeting Meaningful Engagement of Women in HIV Treatment Research Wednesday 16 May 2018, Park Inn Hotel, Brussels, Belgium   The Meeting: Within the framework of the…

Inovio and The Wistar Institute to advance vaccines against TB & malaria

Inovio and The Wistar Institute receive more than $4.6 million in R&D funding to advance vaccines against TB & malaria PLYMOUTH MEETING, Pa., Feb. 12, 2018 -- Inovio Pharmaceuticals, Inc.…

Otsuka to advance development of novel TB compound

Otsuka awarded grant to advance development of novel TB compound OPC-167832 with delamanid TOKYO, Japan & PRINCETON, NJ, USA I January 29, 2018 -- Otsuka Pharmaceutical Co., Ltd., and its…

1 2 3 6